Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors

PURPOSE: Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects against EGFR mutant lung cancer, patients ultimately develop resistance by multiple mechanisms. We therefore assessed the ability of combined treatment with the Met inhibitor crizotinib and new generatio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Nanjo, Shigeki, Yamada, Tadaaki, Nishihara, Hiroshi, Takeuchi, Shinji, Sano, Takako, Nakagawa, Takayuki, Ishikawa, Daisuke, Zhao, Lu, Ebi, Hiromichi, Yasumoto, Kazuo, Matsumoto, Kunio, Yano, Seiji
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3873434/
https://ncbi.nlm.nih.gov/pubmed/24386407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0084700
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars